Skip to main content

Table 5 Defensin genotypes and infection outcomes.

From: Contribution of alpha- and beta-defensins to lung function decline and infection in smokers: an association study

Polymorphism Genotype Physician visits‡§ Part 1 p Value* Part 2 p Value† Days in bed‡ll Part 1 p Value* Part 2 p Value†
DEFA1/DEFA3        
  DEFA1 only 0.22 (0.07) 0.23 0.05 0.38 (0.16) 0.60 0.36
  DEFA1/DEFA3 0.28 (0.02)    0.51 (0.06)   
DEFB1 G-20A        
  GG 0.27 (0.04) 0.85 0.88 0.49 (0.10) 0.86 0.98
  GA 0.26 (0.03)    0.48 (0.08)   
  AA 0.30 (0.05)    0.54 (0.11)   
DEFB1 C-44G        
  CC 0.28 (0.03) 0.81 0.42 0.53 (0.07) 0.93 0.14
  CG 0.27 (0.04)    0.44 (0.10)   
  GG 0.18 (0.10)    0.28 (0.24)   
DEFB1 G-52A        
  GG 0.29 (0.04) 0.67 0.62 0.47 (0.08) 0.81 0.29
  GA 0.25 (0.03)    0.47 (0.08)   
  AA 0.30 (0.06)    0.62 (0.14)   
  1. Definition of abbreviations: DEFA = alpha-defensin; DEFB = beta-defensin.
  2. *Part 1 of the two-part model involves modeling whether an individual has any physician visits or any days in bed due to lower respiratory infection. P values for global haplotype association derived from logistic regression analysis. Decline in lung function status was included as a factor in the analysis.
  3. †Part 2 of the two-part model involves modeling the average number of physician visits or days in bed due to lower respiratory infection given that it is greater than zero. P values for global haplotype association derived from gamma regression analysis. Decline in lung function status was included as a factor in the analysis.
  4. ‡Mean (SE).
  5. §Mean number of visits to a physician for lower respiratory infections per year.
  6. llMean number of days kept in bed for lower respiratory infections per year.